Consolidated Financial Performance (Unaudited)

Income Statement Highlights:

  • Q2 FY27 Total Income: ₹46,862.0 million (Q2 FY26: ₹41,046.8 million)
  • H1 FY27 Total Income: ₹85,791.0 million (H1 FY26: ₹76,123.1 million)
  • Q2 FY27 Revenue from Operations: ₹45,519.9 million (Q2 FY26: ₹40,009.9 million)
  • H1 FY27 Revenue from Operations: ₹82,921.4 million (H1 FY26: ₹73,721.3 million)
  • Q2 FY27 Profit Before Tax: ₹9,996.5 million (Q2 FY26: ₹8,958.3 million)
  • H1 FY27 Profit Before Tax: ₹17,716.4 million (H1 FY26: ₹16,668.4 million)
  • Q2 FY27 Profit After Tax: ₹6,671.3 million (Q2 FY26: ₹7,791.1 million)
  • H1 FY27 Profit After Tax: ₹11,881.1 million (H1 FY26: ₹14,470.2 million)
  • EPS (Basic): ₹56.48 for Q2 FY27 (₹63.99 for Q2 FY26); ₹99.97 for H1 FY27 (₹119.55 for H1 FY26)

Exceptional Items:

  • Recovery of ₹350 million in Q2 FY27 and H1 FY27 against investment impaired during Q4 FY26
  • Includes recovery of previously impaired real estate investment

Taxation:

  • Company opted for new tax regime (Section 115BAA) from FY 2026-27
  • Total tax expense: ₹5,824.1 million for H1 FY27 (₹3,319.1 million for H1 FY26)

Standalone Financial Performance (Unaudited)

Income Statement Highlights:

  • Q2 FY27 Revenue from Operations: ₹30,713.6 million (Q2 FY26: ₹25,420.3 million)
  • H1 FY27 Revenue from Operations: ₹57,390.9 million (H1 FY26: ₹49,142.0 million)
  • Q2 FY27 Profit After Tax: ₹7,624.8 million (Q2 FY26: ₹7,867.3 million)
  • H1 FY27 Profit After Tax: ₹13,324.5 million (H1 FY26: ₹14,428.9 million)
  • EPS (Basic): ₹63.77 for Q2 FY27 (₹65.80 for Q2 FY26); ₹111.44 for H1 FY27 (₹120.68 for H1 FY26)

Major Development: Occlutech Acquisition

Alkem Medtech Private Limited (wholly owned subsidiary) completed acquisition of 55% equity stake in Occlutech Holding AG on July 16, 2026:

  • Purchase consideration: EUR 97.8 million (approximately ₹10,797.6 million)
  • Cash consideration: ₹8,778.3 million
  • Deferred consideration: ₹2,019.3 million
  • Provisional purchase price allocation: Identifiable assets ₹16,047.8 million, liabilities ₹9,208.6 million
  • Goodwill recognized: ₹7,036.0 million
  • Financial results consolidated from acquisition date

Segment Performance

The Group has three reportable segments following the Occlutech acquisition:

Pharmaceuticals Segment:

  • H1 FY27 Revenue: ₹80,012.4 million (H1 FY26: ₹71,680.6 million)
  • H1 FY27 Segment Result: ₹18,212.7 million (H1 FY26: ₹14,872.7 million)

Biotech Segment:

  • H1 FY27 Revenue: ₹2,496.5 million (H1 FY26: ₹2,940.1 million)
  • H1 FY27 Segment Result: Loss of ₹2,054.2 million (Profit of ₹37.4 million in H1 FY26)

MedTech Segment:

  • H1 FY27 Revenue: ₹1,407.9 million (H1 FY26: ₹50.6 million)
  • H1 FY27 Segment Result: Loss of ₹618.8 million (Loss of ₹124.8 million in H1 FY26)

Subsidiaries and Associates

The consolidated results include 46 entities (37 subsidiaries, 1 associate, 8 subsidiaries of Occlutech Holding AG).

Auditor Qualifications:

  • 5 subsidiaries not reviewed by auditors representing total assets of ₹15,803.8 million and revenue of ₹8,959.0 million for H1 FY27
  • 28 subsidiaries not reviewed by their auditors representing total assets of ₹11,605.5 million
  • 1 associate not reviewed by its auditor with share of loss of ₹11.2 million for H1 FY27

Financial Position

Consolidated Balance Sheet (as of September 30, 2026):

  • Total Assets: ₹230,596.4 million (March 31, 2026: ₹208,729.7 million)
  • Total Equity: ₹156,890.0 million (March 31, 2026: ₹143,489.3 million)
  • Total Liabilities: ₹73,706.4 million (March 31, 2026: ₹65,240.4 million)

Standalone Balance Sheet (as of September 30, 2026):

  • Total Assets: ₹183,095.8 million (March 31, 2026: ₹172,611.3 million)
  • Total Equity: ₹152,065.4 million (March 31, 2026: ₹139,987.6 million)

Cash Flow

Consolidated Cash Flow (H1 FY27):

  • Net cash from operating activities: ₹10,445.8 million
  • Net cash used in investing activities: ₹3,783.1 million
  • Net cash used in financing activities: ₹4,439.2 million

Standalone Cash Flow (H1 FY27):

  • Net cash from operating activities: ₹9,641.5 million
  • Net cash used in investing activities: ₹4,219.6 million
  • Net cash used in financing activities: ₹4,693.8 million

Discontinued Operations

The Generic Business was transferred to Alkem Wellness Limited (wholly owned subsidiary) effective October 1, 2025, and is presented as discontinued operations.